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Abstract The goal of our present studies has been to find novel
ryanodine receptor (RyR1) interacting polypeptides that mod-
ulate the channel activity from the luminal side of RyR1. Using
K+ as charge carrier for recording of single channel events
here we demonstrate a very unexpected observation that
troponin I substantially alters RyR’s gating behavior, and
that RyR1 in association with troponin I becomes a rectifying
Ca2+ release channel. Troponin I rapidly locks the RyR1 in a
non-conducting state only at a negative holding potential, and
only when applied to the luminal side; switching to a positive
holding potential results in the channel returning to its original
activity, immediately. A hypothesis is proposed to account
for how an intraluminally located, positively charged molecule
might function as a RyR1 regulator under physiological
conditions. ß 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
Key words: Ryanodine receptor; Calcium release;
Rectifying channel; Troponin I; Yeast two-hybrid screen;
Skeletal muscle
1. Introduction
The skeletal muscle ryanodine receptor (RyR1) in the ter-
minal cisternae of the sarcoplasmic reticulum (SR) has an
essential role in intracellular signalling by mediating the rapid
Ca2 release from the SR. RyR1 belongs to a superfamily of
intracellular Ca2 release channels and is one of the key pro-
teins involved in the excitation^contraction coupling of skel-
etal muscle. As a response to depolarization of the surface
membrane RyR1 initiates Ca2 release from the lumen into
the cytosol [1,2]. The functional unit of RyR1 consists of four
identical 560 kDa proteins and four 12 kDa FK506 binding
proteins [3,4]. Each RyR1 monomer forms membrane span-
ning segments in the C-terminal region [5,6] and the luminal
loop between transmembrane regions may serve as part of the
ion conduction pore [7,8]. The regulation of this channel from
the cytoplasmic (cis) side has been studied extensively [9,10].
Phosphorylation on Ser 2843, which also occurs endogenously
to a signi¢cant extent [11], leads to an enhanced open prob-
ability (Po) by increasing the sensitivity towards ATPcis and
Ca2cis [12].
During the last years accumulating evidence has shown that
also events occurring within the SR lumen are essential for
modulating the Ca2 release process. The existence of an en-
dogenous phosphorylation system in the lumen has been re-
ported by Shoshan et al. [13^15]. Later we could show that
calsequestrin, depending on its phosphorylation state, selec-
tively controls the SR Ca2 release channel activity [16] and
surface plasmon resonance studies stated the high a⁄nity mo-
lecular interaction of RyR1 with calsequestrin [17]. All these
results emphasize the potential and speci¢city of phosphory-
lation-induced changes in protein interactions as signal trans-
fer mechanism [18].
The goal of our present studies was to unveil further novel
RyR1 interacting polypeptides that modulate the channel ac-
tivity from the luminal side of RyR1. Our experiments pre-
sented here show that, when applied to the luminal side and
only at negative holding potential, troponin I inactivates the
SR Ca2 release channel. This inactivation is a result of a
non-conducting state, occurring in response to the negative
holding potential and can immediately be restored by switch-
ing the holding potential to a positive value, i.e. troponin I
recti¢es the Ca2 gating of RyR1 very speci¢cally.
2. Materials and methods
2.1. Yeast two-hybrid screen
The M1/M2 loop (bp 13740^13920) and the M3/M4 loop (bp
14577^14751) of the RyR1 [6] were ampli¢ed via reverse transcrip-
tion-PCR from rabbit skeletal muscle mRNA. For the ¢rst strand
synthesis the primer 5P-CACTTGCTCCTGCTGGT-3P was used.
The primers selected for the PCR (for M1/M2 loop 5P-CGGAATTC-
AAGGTCTCAGACTCTCCAC-3P and 5P-AAAGGTCGACCTCCA-
TGTAGCCCGTGCTC-3P ; for M3/M4 loop 5P-CGGAATTCCGCA-
AGTTCTACAACAAGAG-3P and 5P-AAAGGTCGACGTCGAAG-
ACCACCCGGTA-3P) also introduced the restriction sites EcoRI and
SalI. These restriction sites allowed the cloning of the loops into the
PAS2-1 yeast two-hybrid vector from Clontech. With the M3/M4
loop containing construct as bait a human skeletal muscle Match-
maker cDNA library using the yeast cells CG1945 from Clontech
was screened. In the ¢rst step 365 clones were positive-related to the
activity of the ¢rst reporter gene (grown on His-de¢cient medium). In
the second step 156 positive clones were detected which were success-
ful in activating the second reporter gene (expression of L-galactosi-
dase). The following yeast mating step (exclusion of the housekeeping
genes in the reporter gene activation) resulted in 19 positive clones.
For direct interaction tests the selected positive clones were isolated
and cotransformed with the M1/M2 loop ^ cloned before in PAS2-1 ^
into the yeast cells CG1945 and the transformants were then handled
as described above.
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DNA sequencing was carried out with the DNA sequencing kit in
ABI PRISM and the software Lasergene of DNASTAR was used for
analyzing the sequence data.
2.2. Preparations
Heavy SR vesicles were isolated from rabbit (New Zealand white)
longissimus dorsi and were used immediately for the puri¢cation of
the solubilized RyR channel complex as described previously [16].
Holotroponin was prepared from rabbit skeletal muscle [19] and its
subunits, troponin T, I and C, were obtained as previously described
[20].
2.3. Single channel measurements
The CHAPS (3-[(3-cholamido-propyl)dimethylammonio]-1-pro-
pane-sulfonate)-solubilized RyR1 was incorporated into a Mu«ller^Ru-
din type planar lipid bilayer [21]. Bilayers were formed across a 250
Wm aperture on the delrin cup (Warner Instruments, Campden, NJ,
USA) using a mixture of phosphatidylethanolamine, phosphatidylser-
ine and L-K- phosphatidylcholine at a weight ratio of 5:4:1 dissolved
in n-decane up to a ¢nal concentration of 20 mg/ml. Incorporation of
the RyR1 into the bilayer was initiated in symmetric bu¡er solution
(250 mM KCl, 100 WM EGTA, 150 WM CaCl2, 20 mM PIPES, pH
7.2). Small aliquots of the solubilized receptor were added to one side
of the bilayer chamber de¢ned as the cis (cytoplasmic) side. Orienta-
tion of the incorporated receptor was veri¢ed at the last step of each
single experiment using ryanodine or ruthenium red additions. Suc-
cessful incorporation was detected as a step like increase of membrane
current. Electric potential is given as potential of the cis chamber
relative to the potential of the trans chamber, which was kept at
ground potential. Current signals were ¢ltered at 1 kHz using an eight
pole low-pass Bessel ¢lter, the ¢ltered signal was digitized at 3.3 kHz,
at 12 bit resolution using an Axopatch 200 ampli¢er with Digidata
1200 interface (Axon Instruments Inc., Union City, CA, USA). After
changing the conditions in the chamber, at least 5 min were allowed to
reach the new equilibrium and total recording time was more than
5 min for each experimental condition. Po values were calculated from
representative data segments of 50^100 s duration using the pClamp
6.02 software package of Axon Instruments. Free [Ca2] was calcu-
lated according to [22].
3. Results and discussion
The search for intraluminally located RyR1 interacting pro-
teins by means of the yeast two-hybrid method [23] resulted in
19 positive clones. cDNA sequencing of these clones revealed
six independent clones of the skeletal muscle troponin, two
positive clones were identi¢ed as skeletal muscle protein C
and the remaining 11 clones were disregarded because they
did not represent muscle speci¢c proteins. These results ¢rst
draw our attention to troponin. To analyze this surprising
observation ¢rst we performed direct two-hybrid tests also
with the M1/M2 loop of RyR1. The results of these tests
stated the above observation, both loops, M1/M2 and M3/
M4, interact speci¢cally with skeletal muscle troponin. To
see whether this peculiar ¢nding could have consequences
on the RyR1 channel activity, electrophysiological experi-
ments were carried out.
Following isolation of the subunits of the skeletal muscle
troponin complex, ¢rst, the e¡ect of troponin I on RyR1 was
studied in single channel measurements. The SR calcium
channel is not permeable to Cl ions, but it conducts mono-
valent cations more e⁄ciently than Ca2 [24]. Thus K in-
stead of Ca2 was selected as current carrier for recording of
single channel events in these experiments.
After incorporation ^ at symmetrical 50 WM [Ca2] on both
the cytosolic (cis) and the lumenal (trans) side of the chamber,
resulting in a close to maximal channel activation ^ RyR1
displayed polarity-independent gating characteristics with a
Po = 0.405 þ 0.11 and d= 0.72 þ 0.12 ms (mean þ S.E.M.,
n = 7) (Fig. 1a). Following addition of troponin I to the trans
side ^ but not to the cytosolic (cis) side ^ the gating character-
istics of RyR1 are dramatically altered. In the presence of 200
nM troponin Itrans the channel retains its original gating be-
havior at a positive holding potential. At a negative bilayer
potential (cis relative to trans), the channel, after a period of
regular gating, suddenly locks into a closed state (Fig. 1b).
The channel still functions even though its Po is almost zero,
as demonstrated at the left side of the trace in Fig. 1c. Chang-
ing the holding potential back to the positive sign resulted in
the channel promptly opening and its gating pattern and con-
ductance were immediately restored for the given current di-
rection (compare Fig. 1c with the right part of Fig. 1a). Once
developed, this polarity-dependent gating behavior was main-
tained inde¢nitely, i.e. so long as the membrane remained
intact.
Fig. 2 shows that at a positive holding potential the channel
exhibited ‘control like’ gating, while switching the holding
Fig. 1. E¡ect of troponin Itrans on RyR1 channel gating. Charge
carrier 250 mM K, free [Ca2] of 50 WM at cis and trans sides.
a: Current traces obtained after incorporation of the channel, at a
holding potential of Hp =340 mV (left side of a, marked with
dashed line) and at Hp = +40 mV (right side of a, marked with dot-
ted line) (overshot is due to the polarity change, consequence of the
membrane capacity recharge to the new potential). The channel gat-
ing is identical at both polarities. b: Current traces at negative hold-
ing potential (Hp =340 mV) after the addition of 200 nM troponin
Itrans. Following the mixing, the channel enters a new gating mode,
resulting in an apparent closed state which is distinguished from the
ruthenium red-blocked channel only from the noise spectrum.
c: This peculiar gating mode is characterized by an apparent closed
state at negative holding potential only (left side of c, dashed line),
since changing the holding potential to positive, the channel gating
is similar to that before addition of troponin I (compare right sides
of c and a, dotted line). Transition time required for the gating
mode change is less than the time required for the capacitive transi-
ent to diminish (about 25 ms). Note the very rare ‘extinguished’
opening events, showing that the channel is still present in the bi-
layer and attempts to open (left side of c).
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potential to a negative value resulted in the channel immedi-
ately locking into a closed state where it remained. The onset
of this blocking behavior was delayed by a few seconds after
addition of troponin I. This delay might be due to a di¡usion-
controlled movement of troponin I to the ion conducting
pore. At constant negative holding potential the channel is
locked and becomes inactivated, however, that is still present
in the bilayer as it can be deduced from the observed rare
opening attempts. The formation of this rectifying state is
concentration-independent in the range between 0.2 WM and
2.7 WM troponin I.
To further clarify this surprising e¡ect of troponin I the
in£uences of troponin T, troponin C and histone were ana-
lyzed exactly as described above (Fig. 3).
None of these agents a¡ected RyR1 activity at all, nor did
they induce any polarity- or concentration-dependent channel
gating.
To avoid the possibility of a contaminating component in
the isolated troponin I ^ which might be responsible for the
modulation of RyR1 gating ^ exactly the same single channel
measurements were carried out in the absence and presence of
human cardiac recombinant troponin I.
In the absence of the recombinant cardiac troponin I the
channel gating was identical at positive and at negative hold-
ing potentials (Fig. 4a,b) and characterized by
Po = 0.391 þ 0.074 and d= 0.70 þ 0.15 ms (n = 5). Addition of
the recombinant troponin I did not alter the gating of the
RyR1 at a positive holding potential (Fig. 4c), however, at
negative holding potential the channel was locked into a non-
conducting state, and again short opening events could be
observed. When the holding potential was switched to the
positive range the channel gating was promptly and com-
pletely restored (Fig. 4d). On applying repetitive polarity
changes, the RyR1 went into a long-standing closed state ex-
clusively at negative holding potential, with a Po value of
almost zero.
These experiments show for the ¢rst time that, when ap-
plied to the luminal side and only at negative holding poten-
Fig. 2. Polarity-dependent gating mode sustained. The unique fash-
ion of gating is maintained inde¢nitely, independently of duration
of the applied potentials nor the frequency of polarity changes.
Holding potential set to 43 mV. Note that the reported behavior is
independent of the value of the applied holding potential, as tested
in the range of 10 mV to 90 mV (absolute values). The lowest possi-
ble holding potential is determined by the noise of the current am-
pli¢er, limiting it to about 10 mV.
Fig. 3. E¡ect of troponin C, troponin T and histone on the RyR1
channel activity. Channel current recorded at positive and at nega-
tive holding potential of 40 mV. Charge carrier 250 mM K, free
[Ca2] of 50 WM at cis and trans sides using Ca2-EGTA bu¡er.
a: Representative current trace in the absence of modulators. b:
Representative current record in the presence of 2 WM troponin
Ctrans. c : Representative current record in the presence of 2 WM tro-
ponin Ttrans. d: Representative current record in the presence of 20
WM histonetrans.
Fig. 4. E¡ect of human recombinant cardiac troponin Itrans on
RyR1 channel activity. a,b: Channel current recorded at positive (a)
and negative (b) holding potential of 80 mV. Channel gating is po-
larity- and potential (not shown)-independent. Charge carrier 250
mM K, free [Ca2] of 50 WM at cis and trans sides. c,d: Current
records after the addition of 200 nM recombinant cardiac troponin
I to the trans side of the chamber. Note the unique recti¢er type be-
havior of the channel, which is basically identical to the unique rec-
tifying character of the native skeletal muscle troponin I, composed
of ‘normal’ gating at positive holding potential, while ‘apparently
closed’ state at negative potential, containing only occasionally a
few attempts to open (compare to Fig. 1).
FEBS 25910 28-3-02
M. Varsa¤nyi et al./FEBS Letters 515 (2002) 155^158 157
tial, troponin I inactivates the SR Ca2 release channel. This
inactivation is a result of a non-conducting state, occurring in
response to the negative holding potential, and can immedi-
ately be restored by switching the holding potential to a pos-
itive value. In our experiments troponin I ^ in the role of a
luminally acting positively charged inactivating molecule ^
recti¢es the Ca2 gating of RyR1 very speci¢cally. Our ¢nding
is very surprising and its physiological relevance is completely
open. The transient inactivation of the RyR1 channel by a
functional interaction with troponin I leads to a transient
prompt inhibition of the Ca2 release from the SR lumen
into the cytosol. Troponin I is a strong basic protein (pI
8.9) and under physiological conditions it might interact
with the acidic residues of the pore forming segment, which
exhibits an estimated pI value of ca. 4.1 using its amino acid
sequence information reported in [7]. These electrostatic inter-
actions might help troponin I to ¢nd the right orientation for
locking the channel into a non-conducting state. However,
exclusively at negative holding potential the troponin Itrans
will be ‘¢xed’ and can interrupt the Ca2 release process rap-
idly and very e¡ectively. Furthermore, the transition of the
Ca2 release channel into a non-conducting state is very spe-
ci¢c for troponin I, neither the basic protein histone, nor
other subunits of the troponin complex, troponin C or tropo-
nin T are capable of inducing the same substate.
One might speculate as to the physiological role of these
¢ndings: Ca2 release through the RyR channel generates a
transient negative inside potential of the SR lumen. Relaxa-
tion caused by the reuptake of Ca2 by the Ca2 transport
ATPase reduces continuously this transient negative potential.
Even during Ca2 release the calcium pump starts to work,
and the membrane potential of the SR is determined by the
net calcium £ux.
At negative potential a troponin I like intraluminally lo-
cated regulator, a polypeptide with similar structure and
charge characteristics, locks the RyR1 into a non-conducting
state, allowing no Ca2 £ux through the channel. It forces the
channel to stay closed until the myoplasmic [Ca2] declines
below a certain level thereby accelerating the relaxation pro-
cess. Unfortunately, the noise associated with our bilayer
measurements did not allow the determination of the voltage
threshold at which the troponin I-induced e¡ect starts.
This model provides a possible mechanism for an essential
step, in the e¡ective, reversible inhibition of Ca2 £uxing
through RyR1, which should be fast enough to terminate
Ca2 release during relaxation.
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